New York City-based Pfizer is considering the sale of several cardiology, urology and primary care treatments, a source told Bloomberg. Here are four things to know. 1. Pfizer is working with ...

(Bloomberg) -- Pfizer Inc. will pay $4.9 billion for the obesity startup Metsera Inc. in a bid to catch up to rival drugmakers after failing to compete with its own weight-loss medications. The US ...

(Bloomberg) -- Pfizer Inc. agreed to buy Metsera Inc. for up to $10 billion, prevailing over Novo Nordisk A/S in a tumultuous bidding war after US regulatory opposition thwarted the Danish drugmaker’s ...

(Bloomberg) -- Pfizer Inc. Chief Executive Albert Bourla had long searched for an obesity drug to make up for dwindling sales of the pharma company’s aging blockbusters. Late Friday, after a dramatic ...

(Bloomberg) -- Around dinnertime on Sept. 25, President Donald Trump took to social media to announce a fresh round of tariffs on drugs. The Truth Social post seemingly came out of nowhere, rattling ...

Pfizer Inc. is looking to sell its remaining stake in Covid-19 vaccine partner BioNTech SE, a remnant from one of the pandemic’s most lucrative collaborations. The US drugmaker is offering about 4.55 ...

Pfizer Inc.’s Tukysa, when given as part of the initial treatment for an advanced form of breast cancer, delayed tumor growth by more than eight months, according to a study that may expand its use.

Pfizer Inc. is cutting hundreds of jobs in Switzerland as part of a multi-year program to reduce costs, according to people familiar with the matter. The US drugmaker will reduce its workforce in the ...

On this episode of Stock Movers: - Shares of Nike (NKE) moved higher in premarket trading after signs turnaround efforts at the world’s largest sportswear company are starting to pay off. Sales fell 1 ...